Business as usual? How the pharmaceutical industry protected its long-term interests during and after eurozone bailouts (2011–2020)

References

• Acordo bienal 2012/2013 entre o Estado Português e a Indústria Farmacêutica. 2012. Accessed November 30, 2022. https://portalacordo.infarmed.pt/Files/Acordo_MS_APIFARMA_assinado_vf_2012.pdf.
   Google Scholar
• Acordo de 2014 entre o Estado Português e a Indústria Farmacêutica. 2014. Accessed November 30, 2022. https://portalacordo.infarmed.pt/Files/Acordo_Apifarma_2014_vass.pdf.
   Google Scholar
• Acordo de 2015 entre o Estado Português e a Indústria Farmacêutica. 2014. Accessed November 30, 2022. https://portalacordo.infarmed.pt/Files/Acordo_MF-MS-IF_2015_vf.pdf.
   Google Scholar
• Acordo trienal 2016-2018 entre o Estado Português e a Indústria Farmacêutica. 2016. Accessed November 30, 2022. https://portalacordo.infarmed.pt/Files/Acordo_APIFARMA_2016.pdf.
   Google Scholar
• Aditamento de 2013 ao acordo bienal 2012/2013 entre o Estado Português e a Indústria Farmacêutica. 2013. Accessed November 30, 2022. https://portalacordo.infarmed.pt/Files/Aditamento%20APIFARMA_vass.pdf.
   Google Scholar
• Aditamento de 2017 ao acordo trienal 2016-2018 entre o Estado Português e a Indústria Farmacêutica. 2017. Accessed November 30, 2022. https://portalacordo.infarmed.pt/Files/Acordo_APIFARMA_Aditamento.pdf.
   Google Scholar
• Anexo II ao Acordo de 2015 entre o Estado Português e a Indústria Farmacêutica. 2014.
   Google Scholar
• Angell, M. 2004. “Excess in the Pharmaceutical Industry.” Canadian Medical Association Journal 171 (12): 1451–1453. doi:10.1503/cmaj.1041594
   Web of Science ®Google Scholar
• APIFARMA. 2012a. EFPIA alerta que Indústria Farmacêutica não pode ser ‘alvo fácil’ de medidas de austeridade, May 8. Accessed November 22, 2022. https://www.apifarma.pt/salaimprensa/noticias/Paginas/EFPIAalertaqueIndústriaFarmacêuticanãopodeser“alvofácil”demedidasdeausteridade.aspx.
   Google Scholar
• APIFARMA. 2012b. Medicamentos: Federação Europeia defende solução negociada entre governo e indústria, May 8. Accessed November 23, 2022. https://www.apifarma.pt/salaimprensa/noticias/Paginas/MedicamentosFederaçãoeuropeiadefendesoluçãonegociadaentreGovernoeindústria.aspx.
   Google Scholar
• APIFARMA. 2018. The Pharmaceutical Industry in figures. Accessed November 22, 2022. https://www.apifarma.pt/wp-content/uploads/2021/04/IF_em_Numeros_2018.pdf.
   Google Scholar
• Asensio, M., and T. Popic. 2019. “Portuguese Healthcare Reforms in the Context of Crisis: External Pressure or Domestic Choice?” Social Policy & Administration 53 (7): 1003–1017. doi:10.1111/spol.12480
   Web of Science ®Google Scholar
• Baena del Alcazar, M. 2002. “On the Nature of Power: An Examination of the Governing Elite and Institutional Power in Spain, 1939–92.” Public Administration 80 (2): 323–338. doi:10.1111/1467-9299.00306
   Web of Science ®Google Scholar
• Baker, D. 2021. “The Future of the Pharmaceutical Industry: Beyond Government-Granted Monopolies.” Journal of Law, Medicine & Ethics 49 (1): 25–29. doi:10.1017/jme.2021.5
   PubMed Web of Science ®Google Scholar
• Bank of Portugal. 2016. Analysis of Enterprises in the Pharmaceutical Sector. Banco de Portugal. Accessed November 22, 2022. https://www.bportugal.pt/sites/default/files/anexos/pdf-boletim/study_cb_25_2016_en.pdf.
   Google Scholar
• Bank of Portugal. 2017. Profitability of Portuguese and European Enterprises. Banco de Portugal. Accessed November 22, 2022. https://www.bportugal.pt/sites/default/files/anexos/pdf-boletim/study_cb_29_2017_en.pdf.
   Google Scholar
• Belloni, A., D. Morgan, and V. Paris. 2016. Pharmaceutical Expenditure and Policies: Past Trends and Future Challenges. OECD.
   Google Scholar
• Bowen, T. R., J. Chan, O. Dube, and N. S. Lambert. 2016. Reform Fatigue. Stanford University Graduate School of Business, Research Paper No. 3394.
   Google Scholar
• Branco, R., D. Cardoso, A. M. Guillén, S. Sacchi, and D. L. Balbona. 2019. “Here to Stay? Reversals of Structural Reforms in Southern Europe as the Crisis Wanes.” South European Society and Politics 24 (2): 205–232. doi:10.1080/13608746.2019.1640966
   Web of Science ®Google Scholar
• Busemeyer, M. R., and K. Thelen. 2020. “Institutional Sources of Business Power.” World Politics 72 (3): 448–480. doi:10.1017/S004388712000009X
   Web of Science ®Google Scholar
• Buthe, T., A. M. Jacobs, E. Bleich, R. Pekkanen, M. Trachtenberg, K. Cramer, V. Shih, S. E. Parkinson, E. J. Wood, and T. Pachirat. 2015. Transparency in Qualitative and Multi-Method Research: A Symposium.
   Google Scholar
• Campos, A. 2017. Entrevista a Pedro Pita Barros: ‘É preciso que os orçamentos iniciais tenham compromissos realistas’. Publico Online, January 9. Accessed November 22, 2022. https://www.publico.pt/2017/01/09/sociedade/entrevista/e-preciso-que-orcamentos-iniciais-tenham-compromissos-realistas-1757477.
   Google Scholar
• Cardoso, D., C. Moury, A. P. Costa, and M. Escada. 2021. Governar para as próximas gerações: Sucessos e fracassos de políticas de longo prazo em Portugal (1995-2019). Almedina.
   Google Scholar
• Carone, G., C. Schwierz, and A. Xavier. 2012. Cost-Containment policies in public pharmaceutical spending in the EU (Economic Papers No. 461). European Commission.
   Google Scholar
• Carstensen, M. B., and V. A. Schmidt. 2016. “Power Through, Over and in Ideas: Conceptualizing Ideational Power in Discursive Institutionalism.” Journal of European Public Policy 23 (3): 318–337. doi:10.1080/13501763.2015.1115534
   Web of Science ®Google Scholar
• Chu, A. C. 2008. “Special Interest Politics and Intellectual Property Rights: An Economic Analysis of Strengthening Patent Protection in the Pharmaceutical Industry.” Economics & Politics 20 (2): 185–215. doi:10.1111/j.1468-0343.2007.00328.x
   Google Scholar
• Cioffi, J. W., and K. A. Dubin. 2016. “Commandeering Crisis: Partisan Labor Repression in Spain Under the Guise of Economic Reform.” Politics & Society 44 (3): 423–453. doi:10.1177/0032329216656840
   Web of Science ®Google Scholar
• Corporate Europe. 2021. Big Pharma’s lobbying firepower in Brussels: At least €36 million a year (and likely far more). Corporate Europe Observatory, May 31.
   Google Scholar
• Criteri e modalita’ con cui l’Agenzia italiana del farmaco determina, mediante negoziazione, i prezzi dei farmaci rimborsati dal Servizio sanitario nazionale. 2019. Italian Ministry of Health & Italian Ministry of Economy and Finance. Accessed 23 November 23, 2022. https://www.gazzettaufficiale.it/eli/id/2020/07/24/20A03810/sg.
   Google Scholar
• Culpepper, P. D. 2010. Quiet Politics and Business Power: Corporate Control in Europe and Japan. Cambridge University Press.
   Google Scholar
• Danzon, P. M., Y. R. Wang, and L. Wang. 2005. “The Impact of Price Regulation on the Launch Delay of new Drugs—Evidence from Twenty-Five Major Markets in the 1990s.” Health Economics 14 (3): 269–292. doi:10.1002/hec.931
   PubMed Web of Science ®Google Scholar
• da Silva, Á. F. 2016. “Multinationals and Foreign Direct Investment: The Portuguese Experience (1900-2010).” Journal of Evolutionary Studies in Business 1 (2): 40–68.
   Google Scholar
• Dinis, D., and H. F. Coelho. 2012. Resgatados: Os bastidores da ajuda financeira a Portugal. Esfera dos Livros.
   Google Scholar
• Dreher, A., J. E. Stum, and J. R. Vreeland. 2015. “Politics and IMF Conditionality.” Journal of Conflict Resolution 59 (1): 120–148. doi:10.1177/0022002713499723
   Web of Science ®Google Scholar
• Dukelow, F. 2015. “‘Pushing Against an Open Door’: Reinforcing the neo-Liberal Policy Paradigm in Ireland and the Impact of EU Intrusion.” Comparative European Politics 13 (1): 93–111. doi:10.1057/cep.2014.43
   Web of Science ®Google Scholar
• Dyson, K., and K. Featherstone. 1996. “Italy and EMU as a ‘Vincolo Esterno’: Empowering the Technocrats, Transforming the State.” South European Society and Politics 1 (2): 272–299. doi:10.1080/13608749608539475
   Google Scholar
• EFPIA. 2013. Warning: Austerity can Seriously Damage Your Health, April 18. Accessed November 22, 2022. https://www.efpia.eu/news-events/the-efpia-view/blog-articles/130418-warning-austerity-can-seriously-damage-your-health/.
   Google Scholar
• European Commission. 2009. Pharmaceutical Sector Inquiry: Final Report. European Commission, Competition DG.
   Google Scholar
• European Commission. 2011. Portugal: Memorandum of Understanding on specific economic policy conditionality. Accessed January 5, 2023. https://ec.europa.eu/economy_finance/eu_borrower/mou/2011-05-18-mou-portugal_en.pdf.
   Google Scholar
• Facchinetti, N. J., and W. M. Dickson. 1982. “Access to Generic Drugs in the 1950s: The Politics of a Social Problem.” American Journal of Public Health 72 (5): 468–475. doi:10.2105/AJPH.72.5.468
   PubMed Web of Science ®Google Scholar
• Fernandes, I., M. C. Rueff, S. Portela, and A. Mansinho. 2015. “Impact of the Economic Crisis in the Approval of new Oncological Drugs: The Portuguese Paradigm.” Impact of the Economic Crisis in the Approval of New Oncological Drugs: The Portuguese Paradigm 9: 15–18.
   Google Scholar
• Fierlbeck, K., J. Graham, and M. Herder. 2021. Transparency, Power, and Influence in the Pharmaceutical Industry: Policy Gain or Confidence Game? University of Toronto Press.
   Google Scholar
• Florio, M., and S. Gamba. 2021. “Biomed Europa: After the Coronavirus, a Public Infrastructure to Overcome the Pharmaceutical Oligopoly.” Annals of Public and Cooperative Economics 92 (3): 387–409. doi:10.1111/apce.12341
   Google Scholar
• Flyvbjerg, B. 2006. “Five Misunderstandings About Case-Study Research.” Qualitative Inquiry 12 (2): 219–245. doi:10.1177/1077800405284363
   Web of Science ®Google Scholar
• Fuchs, D. A. 2005. “Commanding Heights? The Strength and Fragility of Business Power in Global Politics.” Millennium 33 (3): 771–801. doi:10.1177/03058298050330030501
   Web of Science ®Google Scholar
• Fuchs, D. A. 2007. Business Power in Global Governance. Boulder, CO: Lynne Rienner.
   Google Scholar
• Fuchs, D. A., and M. M. Lederer. 2007. “The Power of Business.” Business and Politics 9 (3): 1–17. doi:10.2202/1469-3569.1214
   Google Scholar
• Furlong, A., S. A. Aarup, and S. Horti. 2022. Who Killed the COVID Vaccine Waiver? Politico, November 10. Accessed November 22, 2022. https://www.politico.eu/article/covid-vaccine-poor-countries-waiver-killed/.
   Google Scholar
• Gago, A., and C. Moury. 2017. Making and Justifying Impossible Choices: Trade Unions and Three-Level Games in Ireland and Portugal. Paper presented at the Annual Conference of the Council of European Studies, Glasgow.
   Google Scholar
• Gilens, M. 2012. Affluence and Influence. In Affluence and Influence. Princeton University Press.
   Google Scholar
• Godman, B., A. Hill, S. Simoens, A. Kurdi, J. Gulbinovič, A. Martin, A. Timoney, D. Gotham, J. Wale, and T. Bochenek. 2019. “Pricing of Oral Generic Cancer Medicines in 25 European Countries; Findings and Implications.” Generics and Biosimilars Initiative Journal 8 (2): 49–70. doi:10.5639/gabij.2019.0802.007
   Google Scholar
• Goldacre, B. 2014. Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients. Macmillan.
   Google Scholar
• Grande, E. 1996. “The State and Interest Groups in a Framework of Multi-Level Decision-Making: The Case of the European Union.” Journal of European Public Policy 3 (3): 318–338. doi:10.1080/13501769608407037
   Google Scholar
• Hick, R. 2018. “Enter the Troika: The Politics of Social Security During Ireland’s Bailout.” Journal of Social Policy 47 (1): 1–20. doi:10.1017/S0047279417000095
   Web of Science ®Google Scholar
• House of Commons. 2005. The Influence of the Pharmaceutical Industry (Fourth Report of Session 2004–05). House of Commons, Health Committee. Accessed on 23 November 2022. https://publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf.
   Google Scholar
• INFARMED. 2016. Infarmed | Medicamentos Inovadores 2016. Infarmed. Accessed November 23, 2022. https://www.sns.gov.pt/noticias/2017/01/16/infarmed-medicamentos-inovadores-em-2016/.
   Google Scholar
• Informant 10. 2017. Interview 10, December 28.
   Google Scholar
• Informant 11. 2017. Interview 11, December 29.
   Google Scholar
• Informant 1. 2017. Interview 1, November 27.
   Google Scholar
• Informant 12. 2018. Interview 12, January 3.
   Google Scholar
• Informant 13. 2018. Interview 13, January 4.
   Google Scholar
• Informant 14. 2018. Interview 14, January 4.
   Google Scholar
• Informant 15. 2018. Interview 15, January 5.
   Google Scholar
• Informant 16. 2018. Interview 16, January 8.
   Google Scholar
• Informant 17. 2018. Interview 17, January 10.
   Google Scholar
• Informant 18. 2018. Interview 18, January 10.
   Google Scholar
• Informant 19. 2018. Interview 19, January 12.
   Google Scholar
• Informant 20. 2018. Interview 20, January 17.
   Google Scholar
• Informant 2. 2017. Interview 2, December 1.
   Google Scholar
• Informant 22. 2018. Interview 22, February 25.
   Google Scholar
• Informant 26. 2018. Interview 26, February 6.
   Google Scholar
• Informant 27. 2018. Interview 27, February 9.
   Google Scholar
• Informant 28. 2018. Interview 28, February 21.
   Google Scholar
• Informant 29. 2018. Interview 29, February 21.
   Google Scholar
• Informant 30. 2018. Interview 30, May 15.
   Google Scholar
• Informant 3. 2017. Interview 3, December 19.
   Google Scholar
• Informant 4. 2017. Interview 4, December 1.
   Google Scholar
• Informant 6. 2017. Interview 6, December 21.
   Google Scholar
• Informant 9. 2017. Interview 9, December 27.
   Google Scholar
• Jack, A. 2011. Pfizer gets $800m boost for Lipitor. Financial Times, July 10. Accessed November 23, 2022. https://www.ft.com/content/6892b926-aae3-11e0-b4d8-00144feabdc0#axzz1mdwtwufL.
   Google Scholar
• Judge, D., and D. Earnshaw. 2002. “The European Parliament and the Commission Crisis: A new Assertiveness?” Governance 15 (3): 345–374. doi:10.1111/0952-1895.00192
   Web of Science ®Google Scholar
• Kanavos, P., A.-M. Fontrier, J. Gill, and O. Efthymiadou. 2020. “Does External Reference Pricing Deliver What it Promises? Evidence on its Impact at National Level.” The European Journal of Health Economics 21 (1): 129–151. doi:10.1007/s10198-019-01116-4
   PubMed Web of Science ®Google Scholar
• Kapczynski, A. 2022. “The Political Economy of Market Power in Pharmaceuticals.” Journal of Health Politics, Policy and Law.
   PubMed Web of Science ®Google Scholar
• Keller, E. 2018. “Noisy Business Politics: Lobbying Strategies and Business Influence After the Financial Crisis.” Journal of European Public Policy 25 (3): 287–306. doi:10.1080/13501763.2016.1249013
   Web of Science ®Google Scholar
• Khabsa, J., A. Semaan, A. El-Harakeh, A. M. Khamis, S. Obeid, H. A. Noureldine, and E. A. Akl. 2020. “Financial Relationships Between Patient and Consumer Representatives and the Health Industry: A Systematic Review.” Health Expectations 23 (2): 483–495. doi:10.1111/hex.13013
   PubMed Web of Science ®Google Scholar
• Klein, R. 1995. “Paul Pierson, Dismantling the Welfare State? Reagan, Thatcher and the Politics of Retrenchment.” Journal of Public Policy 15 (2): 199–200. doi:10.1017/S0143814X00010151
   Google Scholar
• Klüver, H., C. Braun, and J. Beyers. 2015. “Legislative Lobbying in Context: Towards a Conceptual Framework of Interest Group Lobbying in the European Union.” Journal of European Public Policy 22 (4): 447–461. doi:10.1080/13501763.2015.1008792
   Web of Science ®Google Scholar
• König, P. D., and G. Wenzelburger. 2014. “Toward a Theory of Political Strategy in Policy Analysis.” Politics & Policy 42 (3): 400–430. doi:10.1111/polp.12076
   Google Scholar
• Ladi, S., C. Moury, and F. Stolfi. 2022. Reputation and the Regulation of Pharmacies in Greece and Portugal. Council of European Studies, June, Lisbon.
   Google Scholar
• Lei n.o 8/2012, de 21 de fevereiro, Assembleia da República. 2012.
   Google Scholar
• Lindblom, C. E. 1977. Politics and Markets. Basic Books.
   Google Scholar
• Lisi, M., R. Oliveira, and J. Loureiro. 2021. Looking for Ariadne’s thread: A systematic review on party-group relations in the last 20 years. Politics.
   Google Scholar
• Lukes, S. 2005. Power: A Radical View. Palgrave Macmillan.
   Google Scholar
• Lütz, S., S. Hilgers, and S. Schneider. 2019. “Games Borrower Governments Play: The Implementation of Economic Adjustment Programmes in Cyprus and Portugal.” West European Politics 42 (7): 1443–1463. doi:10.1080/01402382.2019.1583482
   Web of Science ®Google Scholar
• MacCarthaigh, M., and N. Hardiman. 2020. “Exploiting Conditionality: EU and International Actors and Post-NPM Reform in Ireland.” Public Policy and Administration 35 (2): 179–200. doi:10.1177/0952076718796548
   Web of Science ®Google Scholar
• Maloney, W. A., G. Jordan, and A. M. McLaughlin. 1994. “Interest Groups and Public Policy: The Insider/Outsider Model Revisited.” Journal of Public Policy 14 (1): 17–38. doi:10.1017/S0143814X00001239
   Google Scholar
• Mancini, S. 2020. Transparency Matters: Italy Moves Against the Secrecy Surrounding the Cost of Medicines. MSF Access Campaign — Medicines Are Not a Luxury, September 23. Accessed November 22, 2022. https://msf-access.medium.com/transparency-matters-italy-moves-against-the-secrecy-surrounding-the-cost-of-medicines-4468a6e0ced6.
   Google Scholar
• Mandelkern, R., and M. Koreh. 2018. “Interrupting Gradual Institutional Change: How ‘Continuity Agents’ Have Stalled and Even Reversed Gradual Welfare-State Reforms in Israel.” Journal of European Public Policy 25 (11): 1706–1725. doi:10.1080/13501763.2017.1336184
   Web of Science ®Google Scholar
• Mazzoleni, R., and R. R. Nelson. 1998. “Economic Theories About the Benefits and Costs of Patents.” Journal of Economic Issues 32 (4): 1031–1052. doi:10.1080/00213624.1998.11506108
   Web of Science ®Google Scholar
• Mazzucato, M., and H. L. Li. 2021. “A Market Shaping Approach for the Biopharmaceutical Industry: Governing Innovation Towards the Public Interest.” Journal of Law, Medicine & Ethics 49 (1): 39–49. doi:10.1017/jme.2021.8
   PubMed Web of Science ®Google Scholar
• Miller, D., and C. Harkins. 2010. “Corporate Strategy, Corporate Capture: Food and Alcohol Industry Lobbying and Public Health.” Critical Social Policy 30 (4): 564–589. doi:10.1177/0261018310376805
   Web of Science ®Google Scholar
• Morais Nunes, A., D. Cunha Ferreira, and A. Campos Fernandes. 2019. “Financial Crisis in Portugal: Effects in the Health Care Sector.” International Journal of Health Services 49 (2): 237–259. doi:10.1177/0020731418822227
   PubMed Web of Science ®Google Scholar
• Moravcsik, A. 1994. Why the European Community Strengthens the State: Domestic Politics and International Cooperation. Annual Meeting of the American Political Science Association, New York.
   Google Scholar
• Mossialos, E., and A. Oliver. 2005. “An Overview of Pharmaceutical Policy in Four Countries: France, Germany, the Netherlands and the United Kingdom.” The International Journal of Health Planning and Management 20 (4): 291–306. doi:10.1002/hpm.816
   PubMed Web of Science ®Google Scholar
• Moury, C., and A. Afonso. 2019. “Beyond Conditionality: Policy Reversals in Southern Europe in the Aftermath of the Eurozone Crisis.” South European Society and Politics 24 (2)): 155–176. doi:10.1080/13608746.2019.1641945
   Web of Science ®Google Scholar
• Moury, C., D. Cardoso, and A. Gago. 2019. “When the Lenders Leave Town: Veto Players, Electoral Calculations and Vested Interests as Determinants of Policy Reversals in Spain and Portugal.” South European Society and Politics 24 (2): 177–204. doi:10.1080/13608746.2019.1642622
   Web of Science ®Google Scholar
• Moury, C., Ladi, S., Cardoso, D., & Gago, A. 2021a. "Capitalising on Constraint: Bailout Politics in Eurozone Countries." In Capitalising on Constraint. Manchester University Press.
   Google Scholar
• Moury, C., S. Ladi, D. Cardoso, and A. Gago. 2021b. “The Politics of Conditionality: A Theoretical Framework.” In Capitalising on Constraint, 16–29. Manchester University Press.
   Google Scholar
• Moury, C., and A. Standring. 2017. “‘Going Beyond the Troika’: Power and Discourse in Portuguese Austerity Politics.” European Journal of Political Research.
   PubMed Web of Science ®Google Scholar
• Nunes, A. M., D. C. Ferreira, A. de Matos, and R. M. Julião. 2020. “The Portuguese Generic Medicines Market: What’s Next?” Health Policy 124 (4): 397–403. doi:10.1016/j.healthpol.2020.02.014
   PubMed Web of Science ®Google Scholar
• OECD. 2017. Tackling Wasteful Spending on Health. OECD Publishing.
   Google Scholar
• Orçamento do Estado para 2015, no. Lei n.o 82-B/2014, Assembleia da República. 2014.
   Google Scholar
• Patashnik, E. M. 2014. "Reforms at Risk." In Reforms at Risk. Princeton University Press.
   Google Scholar
• Pereira, D. J. T. 2018. A Política do medicamento e a troika: Entre constrangimentos internos e oportunidades externas [Universidade Nova de Lisboa]. Accessed November 23, 2022. https://run.unl.pt/handle/10362/58337.
   Google Scholar
• Pereira, D. J. 2019. Estratégias de mobilização e a crise económica: O caso da indústria farmacêutica. In Grupos de Interesse e Crise Económica em Portugal, 237–263. 1st ed. Edições Sílabo.
   Google Scholar
• Permanand, G., and E. Mossialos. 2005. “Constitutional Asymmetry and Pharmaceutical Policy-Making in the European Union.” Journal of European Public Policy 12 (4): 687–709. doi:10.1080/13501760500160607
   Web of Science ®Google Scholar
• Persson, U., and B. Jönsson. 2016. “The end of the International Reference Pricing System?” Applied Health Economics and Health Policy 14 (1): 1–8. doi:10.1007/s40258-015-0182-5
   PubMed Web of Science ®Google Scholar
• Pires, L. R., and N. Martins. 2015. Segredos de Estado. Editora Matéria-Prima.
   Google Scholar
• Portaria n.o 290-B/2016, Ministério da Saúde. 2016.
   Google Scholar
• Portaria n.o 30-B/2007, de 5 de janeiro, Ministérios da Economia e Inovação e da Saúde. 2007.
   Google Scholar
• Portaria n.o 618-A/2005, de 27 de julho, Ministérios da Economia e Inovação e da Saúde. 2005.
   Google Scholar
• Protocolo com a Apifarma que define redução na despesa do SNS com medicamentos hospitalares e de ambulatório. 2012. Governo de Portugal, Ministério da Saúde. Accessed November 23, 2022 https://www.portugal.gov.pt/media/601172/20120514_ms_protocolo_apifarma.pdf.
   Google Scholar
• Randall, W. 2007. Patent pendulum. Accessed November 23, 2022. https://www.drugdiscoverynews.com/patent-pendulum-1312.
   Google Scholar
• Relator Fernando Bento. 2015. Parecer do Conselho Consultivo da PGR sobre o Acordo bienal 2012/2013 entre o Estado Português e a Indústria Farmacêutica. Accessed November 23, 2022. http://www.dgsi.pt/pgrp.nsf/7fc0bd52c6f5cd5a802568c0003fb410/b713bb3b1390b37a80257ed7002f8b24?OpenDocument.
   Google Scholar
• Rickard, S. J., and T. L. Caraway. 2019. “International Demands for Austerity: Examining the Impact of the IMF on the Public Sector.” The Review of International Organizations 14 (1): 35–57. doi:10.1007/s11558-017-9295-y
   Web of Science ®Google Scholar
• Roemer-Mahler, A. 2013. “Business Conflict and Global Politics: The Pharmaceutical Industry and the Global Protection of Intellectual Property Rights.” Review of International Political Economy 20 (1): 121–152. doi:10.1080/09692290.2011.645848
   Web of Science ®Google Scholar
• Sarpatwari, A., and A. S. Kesselheim. 2021. “Introduction: Public Sector and non-Profit Contributions to Drug Development—Historical Scope, Opportunities, and Challenges.” Journal of Law, Medicine & Ethics 49 (1): 6–9. doi:10.1017/jme.2021.2
   PubMed Web of Science ®Google Scholar
• thepharmaletter. 2012. EFPIA President Warns that European Pricing Threatens Medicines Supply Flow, June 26. Accessed November 22, 2022. https://www.thepharmaletter.com/article/efpia-president-warns-that-european-pricing-threatens-medicines-supply-flow.
   Google Scholar
• Tompson, W., and R. Price. 2009. The Political Economy of Reform: Lessons from Pensions, Product Markets and Labour Markets in Ten OECD Countries. OECD.
   Google Scholar
• Treacy, K. P., and N. Watson-Doig. 2016. What is Parallel Trade and How Does it Affect Pharma? Comp Law, December 1. Accessed November 22, 2022. https://knect365.com/complaw-blog/article/073ed81f-0d17-4c0e-a819-38ff60332dec/what-is-parallel-trade-and-how-does-it-affect-pharma.
   Google Scholar
• Vogler, S., N. Zimmermann, A. Ferrario, V. J. Wirtz, K. de Joncheere, H. B. Pedersen, G. Dedet, V. Paris, A. K. Mantel-Teeuwisse, and Z.-U.-D. Babar. 2016. “Pharmaceutical Policies in a Crisis? Challenges and Solutions Identified at the PPRI Conference.” Journal of Pharmaceutical Policy and Practice 9(1): 1–5. Springer.
   PubMedGoogle Scholar
• Vreeland, J. R. 2005. The International and Domestic Politics of IMF Programs. Yale University.
   Google Scholar
• Wilks, S. 2013. The Political Power of the Business Corporation. Edward Elgar Publishing.
   Google Scholar
• Williamson, J. 1994. The Political Economy of Policy Reform. Peterson Institute.
   Google Scholar
• Woll, C. 2019. “Corporate Power Beyond Lobbying.” American Affairs 3 (3): 38–55.
   Google Scholar
• Wouters, O. J., L. A. Berenbrok, M. He, Y. Li, and I. Hernandez. 2022. “Association of Research and Development Investments with Treatment Costs for New Drugs Approved from 2009 to 2018.” JAMA Network Open 5 (9): e2218623–e2218623. doi:10.1001/jamanetworkopen.2022.18623
   PubMed Web of Science ®Google Scholar
• Young, K., and S. Pagliari. 2017. “Capital United? Business Unity in Regulatory Politics and the Special Place of Finance.” Regulation & Governance 11 (1): 3–23. doi:10.1111/rego.12098
   Web of Science ®Google Scholar